Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 open-label long-term safety study in pediatric developmental and epileptic encephalopathies
ACTRN12618000516280Phase 2Recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Zygel in epilepsy and epileptic encephalopathy, sponsored by Zynerba Pharmaceuticals. Primary endpoint: Safety and tolerability of ZYN002. Started Apr 2018; status: recruiting.
02
Drugs
Zygel
03
Conditions
epilepsyepileptic encephalopathy
Beyond the preview
Go deeper on ACTRN12618000516280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000516280.